Endo Scheduled Insulin Vs Noninsulin Therapies

---
name: endo-scheduled-insulin-vs-noninsulin-therapies
description: Recommends scheduled insulin therapy over noninsulin agents for glycemic management in most adult hospitalized patients with hyperglycemia (with or without known type 2 diabetes) during noncritical illness. Trigger phrases include new hyperglycemia without prior diabetes, known type 2 diabetes, or inpatient hyperglycemia prompting insulin vs noninsulin agent choice.
---

# Prefer scheduled insulin therapy over noninsulin agents for most hospitalized hyperglycemia patients

## STEP 1 — Gather Information
Collect admission blood glucose, diabetes history (type 2), current meds, renal/hepatic function, nutrition status, illness severity (noncritical), and insulin pump use or contraindications. Determine if hyperglycemia (BG >140 mg/dL) is present in a noncritical illness setting.

## STEP 2 — Rule In / Rule Out
Rule out if the patient has select mild hyperglycemia and type 2 diabetes with HbA1c <7.5 %, BG <180 mg/dL, and (if on insulin) total daily dose <0.6 units/kg/day; otherwise rule in for scheduled insulin preference.

## STEP 3 — Classify or Stratify
For patients meeting select criteria, classify as eligible for either DPP4i with correction insulin or scheduled insulin therapy; for all others, classify as preferring scheduled insulin therapy.

## STEP 4 — Decide
For most patients (non-select), initiate scheduled insulin therapy (e.g., basal glargine 0.1‑0.2 units/kg nightly plus prandial rapid‑acting insulin before meals or basal‑plus‑correction regimen). For select patients, either start scheduled insulin therapy or DPP4i with correction insulin as part of a transition plan; if preferring scheduled insulin, choose scheduled insulin.

## Clinical Guardrails / Mimics / Pitfalls
Do not use sliding scale insulin alone; avoid metformin, sulfonylureas, TZDs, GLP‑1RAs, SGLT2is as monotherapy due to hypoglycemia, ketoacidosis, or acute kidney injury risks; reserve DPP4i for select stable patients near discharge; do not discontinue basal insulin in type 1 or insulin‑dependent diabetes; avoid insulin pump therapy without institutional expertise.

## Concrete Clinical Example
A 65‑year‑old woman admitted for cellulitis presents with random BG 168 mg/dL, no prior diabetes, HbA1c 5.8%, normal creatinine. She is noncritically ill. Scheduled insulin therapy is started with glargine 10 units nightly and insulin lispro 4 units before meals; glucose stabilizes 110‑150 mg/dL without hypoglycemia.

**Source:** Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2022, DOI:10.1210/clinem/dgac278